Abstract
Two bismuth(III) porphyrins—5,10,15,20-tetrakis(phenyl)porphyrinatobismuth(III) nitrate, [Bi(III)(TPP)]NO3, and the unprecedent 5,10,15,20-tetrakis(4-carbomethoxyphenyl)porphyrinatobismuth(III) nitrate, [Bi(III)(T4CMPP)]NO3, and two unprecedented antimony(V) porphyrins dichlorido(5,10,15,20-tetrakis(phenyl)porphyrinato)antimony(V) bromide, [Sb(V)(TPP)Cl2]Br, and dibromido(5,10,15,20-tetrakis(4-carbomethoxyphenyl)porphyrinato)antimony(V) bromide, [Sb(V)(T4CMPP)Br2]Br,—were synthesized by reacting the corresponding porphyrin ligand with Bi(NO3)3·5H2O or SbCl3. All compounds were characterized by UV–vis, 1H NMR spectroscopy, and mass spectrometry. The new compounds were also characterized by elemental analysis. Because antimony and bismuth compounds have been widely applied in medicine, the activity of these complexes was tested against Sb-sensitive and -resistant Leishmania amazonensis parasites. [Sb(V)(T4CMPP)Br2]Br was more active against the promastigote form of Sb-resistant mutant strain as compared to the sensitive parental strain, with IC50 in the micromolar range. These data contrasted with those obtained using the Sb(III) drug potassium antimony tartrate, which displayed IC50 of 110 μmol L−1 against the Sb-sensitive parasite and was almost inactive against the Sb-resistant strain. The H2T4CMPP ligand also showed antileishmanial activity against Sb-resistant and -sensitive strains, but with IC50 at least tenfold greater than that of the complex. The Sb(V)-porphyrin complex was also active against intracellular amastigotes and showed a higher selectivity index than the conventional Sb(V) drug glucantime, in both Sb-sensitive and -resistant strains. The greater antileishmanial activity of this complex could be attributed to an increased cellular uptake of Sb. Thus, [Sb(V)(T4CMPP)Br2]Br constitutes a new antileishmanial drug candidate.
Similar content being viewed by others
Abbreviations
- αMEM:
-
Minimum essential culture medium
- BALB/c:
-
Albino mice
- BSS:
-
Bismuth subsalicylate
- CBS:
-
Bismuth subcitrate
- DMF:
-
N,N-dimethylformamide
- FBS:
-
Fetal calf serum
- HEPES:
-
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid
- MTT:
-
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- PBS:
-
Phosphate-buffered saline
- Phen:
-
1,10-Phenanthroline
- RPMI:
-
Roswell Park Memorial Institute (cell culture medium)
- TMS:
-
Tetramethylsilane
- TA:
-
Potassium antimony(III) tartrate
- [Bi(III)(TPP)]NO3 :
-
5,10,15,20-Tetrakis(phenyl)porphyrinatobismuth(III) nitrate
- [Bi(III)(T4CMPP)]NO3 :
-
5,10,15,20-Tetrakis(4-carbomethoxyphenyl)porphyrinatobismuth(III) nitrate
- [Sb(V)(TPP)Cl2]Br:
-
Dichlorido(5,10,15,20-tetrakis(phenyl)porphyrinato)antimony(V) bromide
- [Sb(V)(T4CMPP)Br2]Br:
-
Dibromido(5,10,15,20-tetrakis(4-carbomethoxyphenyl)porphyrinato)antimony(V) bromide
References
Barbour T, Belcher WJ, Brothers PJ, Rickard CEF, Ware DC (1992) Inorg Chem 31:746–754
Michaudet L, Fasseur D, Guilard R, OU Z, Kadish KM, Dahaoiu S, Lecomte C (2000) J Porphyrins Phthalocyanines 4:261–270
Treibs A (1969) Justus Liebigs Ann Chem 728:115–148
Buchler JW, Lay KL (1974) Inorg Nucl Chem Lett 10:297
Halime Z, Michaudet L, Razavet M, Ruzié C, Boitrel B (2003) Dalton Trans 4250–4254
Boitrel B, Breede M, Brothers PJ, Hodgson M, Michaudet L, Rickard CEF, Salim NA (2003) Dalton Trans 9:1803–1807
Balasanthiran V, Chisholm MH (2014) Angew Chem Int Ed 53:1594–1597
Salvador JAR, Pinto RMA, Silvestre SM (2009) Curr Org Synth 6:426–470
Bharti SK, Singh SK (2009) Pharm Lett 1:39–51
Frézard F, Demicheli C, Ribeiro RR (2009) Molecules 14:2317–2336
Modabber F (1993) Leishmaniasis. In: Tropical Disease Research. Progress 1991–92. UNDP/World Bank/WHO Special Programme For Research And Training In Tropical Diseases. Geneva: World Health Organization, 77
Goodwin LC, Page JE (1943) Biochem J 22:236–240
Miekeley N, Mortari SR, Schubach AO (2002) Anal Bioanal Chem 372:495–502
Frézard F, Demicheli C, Ferreira CS, Costa MAP (2001) Antimicrob Agents Chemother 45:913–916
Ferreira CS, Martins PS, Demicheli C, Brochu C, Ouellette M, Frezard F (2003) Biometals 16:441–446
Yan S, Li F, Ding K, Sun H (2003) J Biol Inorg Chem 8:689–697
Denton H, McGregor JC, Coombs GH (2004) Biochem J 381:405–412
Zhou Y, Messier N, Ouellette M, Rosen BP, Mukhopadhyay R (2004) J Biol Chem 279:37445–37451
Demicheli C, Frezard F, Mangrum JB, Farrell NP (2008) Chem Commun 30:4828–4830
Demicheli C, Frézard F, Lecouvey M (2002) Garnier-Suillerot. Biochim Biophys Acta 1570:192–198
Rebouças JS, Spasojevic I, Batinic-Haberle I (2008) J Biol Inorg Chem 13:289–302
Mosmann T (1983) J Immunol Methods 65:55–63
Monte-Neto RL, Coelho AC, Raymond F, Légaré D, Corbeil J, Frézard F, Ouellette M (2011) PLoS Neglected Trop Dis 5:e1167
Lizarazo-Jaimes EH, Monte-Neto RL, Reis PG, Fernandes NL, Speziali MN, Melo MN, Frézard F, Demicheli C (2012) Molecules 17:12622–12635
Moreira D, Neto RLM, Andrade JM, Santi AMM, Reis PG, Frézard F, Murta SMF (2013) Int J Parasitol Drugs Drug Resist 3:143–153
Kadish KM, Smith KM, Guilard R (2000) The porphyrin handbook: inorganic, organometallic and coordination chemistry, vol 3. Elsevier, p 40
Knor G (1994) Vogler. Inorg Chem 33:314–318
Vogel AI (1981) Química analítica qualitativa. São Paulo, Mestre Jou, p 359
Marzochi MC, Marzochi KB (1994) Cad Saude Publica 10:359–375
Frézard F, Demicheli C (2010) Expert Opin Drug Deliv 7:1343–1358
Acknowledgments
We thank CNPq, CAPES, and FAPEMIG for the financial support.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Gomes, M.L., DeFreitas-Silva, G., dos Reis, P.G. et al. Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite. J Biol Inorg Chem 20, 771–779 (2015). https://doi.org/10.1007/s00775-015-1264-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-015-1264-4